Bristol Myers Squibb and Pfizer Launch Eliquis on Mark Cuban's Cost Plus Drugs Platform
Key Insights
Bristol Myers Squibb (search) and Pfizer announced a collaboration with Mark Cuban Cost Plus Drug Company (search) to offer Eliquis (apixaban) on CostPlusDrugs.com starting April 27, 2026.
Patients with a prescription will pay $345 for a 30-day supply of the blockbuster blood thinner, expanding direct-buying options for cash-paying patients.
Eliquis is one of the most widely prescribed oral anticoagulants in the United States and the largest drug brand to be added to the Cost Plus Drugs platform.
Bristol Myers Squibb (search) and Pfizer announced a new collaboration with Mark Cuban Cost Plus Drug Company (search) to make their blockbuster blood thinner Eliquis (apixaban) available through the online pharmacy platform beginning April 27, 2026. The partnership represents a significant expansion of direct-to-patient access options for one of the nation's most widely prescribed oral anticoagulants.
Pricing and Access Details
Patients with a prescription will pay $345 for a 30-day supply of Eliquis on CostPlusDrugs.com. This pricing structure is part of Cost Plus Drugs' transparent model designed to reduce added costs in the pharmaceutical supply chain. The online pharmacy, founded in 2022, allows patients to purchase medicines directly with clearly listed prices and home delivery.
"The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options for accessing Eliquis — a medicine relied upon by millions of Americans daily — to the popular Cost Plus Drugs platform," said Adam Lenkowsky, chief commercial officer at Bristol Myers Squibb (search). "This new collaboration is grounded in a shared commitment to transparency and offers another meaningful solution to overcome access barriers, lower costs and broaden the availability of our medicines for the patients who need them."
Market Significance
Eliquis represents one of the largest drug brands to be added to the Cost Plus Drugs platform. The medication is used to help lower the risk of stroke (search) and blood clots (search) in patients with atrial fibrillation (search), an irregular heartbeat, and to treat blood clots in the legs and lungs. According to the companies, for every 100,000 patients treated, Eliquis has resulted in an estimated $3 billion in total healthcare cost savings and avoidance, including reduced hospitalization and extended rehabilitation needs.
Mark Cuban, co-founder of Cost Plus Drugs, emphasized the patient-centric approach: "We've heard from a lot of people asking for Eliquis on Cost Plus Drugs, and this is about making sure they have a clearer, more direct way to access it. People shouldn't have to guess what they're going to pay for a medication they depend on. When you strip away the layers that drive up costs, you give people more control over how they get their prescriptions."
Expanding Direct-to-Patient Programs
This collaboration builds on the BMS-Pfizer Alliance's existing direct-to-patient initiatives. In 2025, the companies launched a separate direct-to-patient Eliquis program through Eliquis 360 Support, which is also accessible via BMS Patient Connect. The addition of Cost Plus Drugs provides another avenue for cash-paying patients to access the medication directly.
Clinical Applications and Safety Profile
Eliquis is indicated for multiple therapeutic uses in adults, including reducing the risk of stroke (search) and blood clots (search) in people with atrial fibrillation (search) not caused by heart valve problems, treating blood clots in the veins of the legs (deep vein thrombosis (search)) or lungs (pulmonary embolism (search)), and preventing blood clots following hip or knee replacement surgery. The medication is also approved for use in children from birth and older to treat venous thromboembolism after initial anticoagulant treatment.
The most common side effect of Eliquis in adults is bleeding, while in children, the most common side effects include headache, vomiting, and heavy menstrual bleeding. The medication carries important safety warnings regarding increased bleeding risk and the potential for spinal or epidural blood clots (search) in certain medical procedures.
Strategic Partnership Impact
The collaboration reflects both companies' commitment to addressing healthcare access challenges through innovative distribution models. The Bristol Myers Squibb (search)-Pfizer Alliance has established itself as a leader in cardiovascular therapeutics, with particular expertise in stroke (search) prevention and thrombosis management.
Cost Plus Drugs' business model focuses on transparency and cost reduction by eliminating traditional pharmaceutical supply chain markups. The platform's approach aligns with growing industry trends toward direct-to-consumer healthcare solutions and price transparency initiatives.